InvestSmart
-
Stop Treating Marvell and Bausch Like the Same Bet
Jim Cramer gave his take. Fine. But if you’re putting real money to work, you need more than TV conviction. Marvell and Bausch Health sit on opposite ends of the risk spectrum—one riding the AI buildout, the other crawling out from under a mountain of debt. The question isn’t whether they’re “good companies.” It’s whether…
-
Stop Trading TV Tips — Start Trading Levels
Jim Cramer says buy Marvell and Bausch. Fine. But blindly following TV picks is how retail gets chopped up. The real question isn’t whether these are “good companies.” It’s where the trade actually sets up — and where it breaks. Let’s talk levels, tailwinds, and risk. Marvell (MRVL): The AI Toll Booth — But You…
-
Cramer’s Marvell Call Makes Sense — Bausch Looks Like a Stretch
Jim Cramer says “buy” and half of Wall Street either salutes or rolls its eyes. So when he throws out Marvell and Bausch, the real question isn’t what Cramer said. It’s whether you follow him — or fade him. Here’s the actual setup. Marvell (MRVL): This One Deserves Respect Marvell isn’t some speculative dart throw.…
-
Stop Treating Jim Cramer Like an Oracle (He’s a Thermometer)
Jim Cramer says buy, the stock pops. He trashes a name, it tanks. The real question isn’t what he said about Marvell (MRVL) and Bausch Health (BHC). It’s whether you should treat those calls as gospel—or as contrarian signals. Here’s the blunt answer: Cramer is better at spotting narratives than nailing entry points. And in…
You must be logged in to post a comment.